Please login to the form below

Not currently logged in
Email:
Password:

TauRx

This page shows the latest TauRx news and features for those working in and with pharma, biotech and healthcare.

AbbVie takes anti-tau drug into phase II for Alzheimer's

AbbVie takes anti-tau drug into phase II for Alzheimer's

Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in ... TauRx also said it had cognitive benefit in a subset of patients not

Latest news

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    year. TauRx' tau aggregation inhibitor LMTX failed to meet its objective of improving cognition and the ability to carry out everyday tasks in the trial, which involved 891 patients with mild ... TauRx has two other trials in play – one in mild

  • AbbVie and C2N take tau antibody into clinic AbbVie and C2N take tau antibody into clinic

    Other companies working on tau as a target include TauRx Therapeutics, which has a phase III trial ongoing of its lead candidate LTX in Alzheimer's and is due to report

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    Of these, TRx 0237 (leuco-methylthioninium, TauRx Pharmaceuticals), an oral agent shown to inhibit tau aggregation, is in phase III trials in the US and the UK in patients with ... Two agents targeting tau have been discontinued recently at phase II –

  • Lilly acquires Alzheimer’s diagnostics from Siemens Lilly acquires Alzheimer’s diagnostics from Siemens

    Financial terms of the deal were not disclosed. Other companies with an interest in developing tau-targeted products include TauRx Pharmaceuticals, which in November 2012 received $111.8m from Malaysian investment

  • Funding boost for late-stage tau-based Alzheimer’s research Funding boost for late-stage tau-based Alzheimer’s research

    Funding boost for late-stage tau-based Alzheimer’ s research. Singapore company TauRx receives $112m investment to take LMTX treatment into phase III. ... generating such data for at least the next 5-7 years,” said Professor Claude Wischik, executive

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics